trending Market Intelligence /marketintelligence/en/news-insights/trending/SgfPZkVyAqKVkP6RTw4AXw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US FDA rejects AcelRx Pharmaceuticals' pain drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA rejects AcelRx Pharmaceuticals' pain drug

AcelRx Pharmaceuticals Inc. said the U.S. Food and Drug Administration rejected its new drug application for DSUVIA to treat moderate-to-severe acute pain.

AcelRx submitted the application in December 2016. In a complete response letter, the U.S. FDA requested additional data on at least 50 patients and certain labeling changes in usage directions.

The 2016 application was supported by results from the entire ARX-04 clinical program, including data from four trials that showed improvement in pain intensity within 15 to 30 minutes of dosage.

"We believe the recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA," AcelRX CEO Vincent Angotti said in a statement.